GB8417194D0
(en)
*
|
1984-07-05 |
1984-08-08 |
Boots Co Plc |
Therapeutic agents
|
CA1341314C
(en)
|
1984-07-06 |
2001-11-06 |
David Cox |
Derivatives of benzimidazole, benzothiazole and benzoxazole
|
GB2161160B
(en)
*
|
1984-07-06 |
1989-05-24 |
Fisons Plc |
Heterocyclic sulphinyl compounds
|
EP0204215B1
(en)
*
|
1985-05-24 |
1993-08-11 |
G.D. Searle & Co. |
2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines
|
US5869513A
(en)
*
|
1985-05-24 |
1999-02-09 |
G. D. Searle & Co. |
2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines
|
US4824856A
(en)
*
|
1985-08-14 |
1989-04-25 |
Nippon Chemiphar Co., Ltd. |
Method of protecting gastrointestinal tract
|
WO1987001114A2
(en)
*
|
1985-08-21 |
1987-02-26 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
New amines, process for their manufacture, their use and medicines containing them
|
AR243167A1
(en)
|
1985-08-24 |
1993-07-30 |
Hoechst Ag |
Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors
|
AU619444B2
(en)
*
|
1986-06-02 |
1992-01-30 |
Nippon Chemiphar Co. Ltd. |
2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
|
EP0251536A1
(en)
*
|
1986-06-24 |
1988-01-07 |
FISONS plc |
Benzimidazoles, their production, formulation and use as gastric acid secretion inhibitors
|
US4772619A
(en)
*
|
1986-07-17 |
1988-09-20 |
G. D. Searle & Co. |
[(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines
|
US4687775A
(en)
*
|
1986-07-17 |
1987-08-18 |
G. D. Searle & Co. |
2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
|
US4721718A
(en)
*
|
1986-08-18 |
1988-01-26 |
G. D. Searle & Co. |
2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers
|
DE3639926A1
(en)
*
|
1986-11-22 |
1988-06-01 |
Hoechst Ag |
SUBSTITUTED THIENOIMIDAZOLTOLUIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND THEIR USE AS AN INGESTIC ACID INHIBITOR
|
IT1222412B
(en)
*
|
1987-07-31 |
1990-09-05 |
Chiesi Farma Spa |
THYOMETHYL AND SULFINYL METHYL DERIVED WITH ANTI-SECRET ACID GASTRIC ACTION, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
JP2614756B2
(en)
*
|
1988-08-10 |
1997-05-28 |
日本ケミファ株式会社 |
Imidazole derivative, method for producing the same, and anti-ulcer agent containing the same
|
JPH06298611A
(en)
*
|
1993-04-16 |
1994-10-25 |
Nippon Chemiphar Co Ltd |
Antibacterial agent
|
SE9301489D0
(en)
|
1993-04-30 |
1993-04-30 |
Ab Astra |
VETERINARY COMPOSITION
|
SE9402431D0
(en)
*
|
1994-07-08 |
1994-07-08 |
Astra Ab |
New tablet formulation
|
SE9500422D0
(en)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9500478D0
(en)
*
|
1995-02-09 |
1995-02-09 |
Astra Ab |
New pharmaceutical formulation and process
|
US5708017A
(en)
*
|
1995-04-04 |
1998-01-13 |
Merck & Co., Inc. |
Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
|
HRP960232A2
(en)
*
|
1995-07-03 |
1998-02-28 |
Astra Ab |
A process for the optical purification of compounds
|
NZ318501A
(en)
*
|
1995-09-21 |
1999-06-29 |
Pharma Pass Llc |
Novel composition containing an acid-labile omeprazole and process for its preparation
|
SE9600070D0
(en)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6380222B2
(en)
|
1996-10-11 |
2002-04-30 |
Astrazeneca Ab |
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
|
WO1999004816A1
(en)
|
1997-07-25 |
1999-02-04 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Proton pump inhibitor in therapeutic combination with antibacterial substances
|
SE9704870D0
(en)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulation I
|
SE9704869D0
(en)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulaton II
|
JP4988088B2
(en)
|
1998-08-12 |
2012-08-01 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Oral dosage form composition of pyridin-2-ylmethylsulfinyl-1H-benzimidazole, a compound having a skeleton of pyridin-2-ylmethylsulfinyl-1H-benzimidazole, or a pharmaceutically acceptable salt thereof is fixed. Composition combined with
|
WO2000027841A1
(en)
*
|
1998-11-06 |
2000-05-18 |
Dong-A Pharmaceutical Co., Ltd. |
Method of preparing sulfide derivatives
|
TWI243672B
(en)
|
1999-06-01 |
2005-11-21 |
Astrazeneca Ab |
New use of compounds as antibacterial agents
|
CA2376202C
(en)
|
1999-06-07 |
2008-11-18 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Novel preparation and administration form comprising an acid-labile active compound
|
SE9903831D0
(en)
|
1999-10-22 |
1999-10-22 |
Astra Ab |
Formulation of substituted benzimidazoles
|
SE0000774D0
(en)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
US6544556B1
(en)
|
2000-09-11 |
2003-04-08 |
Andrx Corporation |
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
SE0101379D0
(en)
|
2001-04-18 |
2001-04-18 |
Diabact Ab |
Composition that inhibits gastric acid secretion
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
SE0102993D0
(en)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
ES2314227T7
(en)
|
2002-04-09 |
2012-11-19 |
Flamel Technologies |
ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A WATERPROOF SUSPENSION OF MICROCAPSULES THAT ALLOW THE MODIFIED RELEASE OF AMOXYLYCIN.
|
ATE419840T1
(en)
|
2002-04-09 |
2009-01-15 |
Flamel Tech Sa |
ORAL AQUEOUS SUSPENSION CONTAINING MICROCAPSULES FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
|
SE0203065D0
(en)
|
2002-10-16 |
2002-10-16 |
Diabact Ab |
Gastric acid secretion inhibiting composition
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
JP4919801B2
(en)
|
2003-09-26 |
2012-04-18 |
アルザ・コーポレーシヨン |
Drug coating providing high drug loading and method for providing the same
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20060024362A1
(en)
|
2004-07-29 |
2006-02-02 |
Pawan Seth |
Composition comprising a benzimidazole and process for its manufacture
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US8541026B2
(en)
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
US7981908B2
(en)
|
2005-05-11 |
2011-07-19 |
Vecta, Ltd. |
Compositions and methods for inhibiting gastric acid secretion
|
US7803817B2
(en)
|
2005-05-11 |
2010-09-28 |
Vecta, Ltd. |
Composition and methods for inhibiting gastric acid secretion
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
CA2648280C
(en)
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
DK2046334T3
(en)
|
2006-07-25 |
2014-08-25 |
Vecta Ltd |
Compositions and Methods to Inhibit Stomach Acid Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI
|
US9205094B2
(en)
|
2006-12-22 |
2015-12-08 |
Ironwood Pharmaceuticals, Inc. |
Compositions comprising bile acid sequestrants for treating esophageal disorders
|
EP2344139A1
(en)
|
2008-09-09 |
2011-07-20 |
AstraZeneca AB |
Method for delivering a pharmaceutical composition to patient in need thereof
|
EA201290026A1
(en)
|
2009-06-25 |
2012-07-30 |
Астразенека Аб |
A METHOD FOR TREATING A PATIENT THAT HAS A RISK OF DEVELOPMENT OF ANALISM ASSOCIATED WITH THE RECEPTION OF NONSTEROID ANTI-INFLAMMATORY MEDIA
|
WO2011080500A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
US20120294937A1
(en)
|
2009-12-29 |
2012-11-22 |
Novartis Ag |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
WO2011080502A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
EP2601947A1
(en)
|
2011-12-05 |
2013-06-12 |
Abo Bakr Mohammed Ali Al-Mehdar |
Fixed-dose combination for treatment of helicobacter pylori associated diseases
|
BR112014016085A8
(en)
|
2011-12-28 |
2017-07-04 |
Pozen Inc |
Enhanced compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
US20160015644A1
(en)
|
2013-01-15 |
2016-01-21 |
Ironwood Pharmaceuticals, Inc. |
Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
|
EP2801565B1
(en)
*
|
2013-05-06 |
2015-07-22 |
King Saud University |
Compounds for use as anti-ulcer agent and/or anti-Helicobacter pylori agent and pharmaceutical compositions thereof
|
US20180015118A1
(en)
|
2015-02-03 |
2018-01-18 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating upper gastrointestinal disorders in ppi refractory gerd
|